Marinus Pharmaceuticals (STU:61Y) Other Income (Expense) : €-5.23 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Marinus Pharmaceuticals Other Income (Expense)?

Marinus Pharmaceuticals's other income expense for the Marinus Pharmaceuticals's pretax income for the three months ended in Sep. 2024 was €0.09 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was €-5.23 Mil.

Marinus Pharmaceuticals Other Income (Expense) Historical Data

The historical data trend for Marinus Pharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Other Income (Expense) Chart

Marinus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

-0.05

-0.03

0.58

98.82

-2.45

Marinus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Income (Expense)	Get a 7-Day Free Trial															0.96	-3.47	0.03	-1.89	0.09

Marinus Pharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.23 Mil.

Marinus Pharmaceuticals (STU:61Y) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Marinus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (STU:61Y) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Marinus Pharmaceuticals Headlines

No Headlines